Eli Lilly and Company is acquiring Ajax Therapeutics in a deal worth up to $2.3 billion to strengthen its blood cancer treatment pipeline.
Glimpse:
Eli Lilly has announced the acquisition of Ajax Therapeutics for up to $2.3 billion, including milestone based payments. The deal focuses on advancing a next generation JAK2 inhibitor for rare blood cancers like myelofibrosis and polycythemia vera.
In a major move to expand its oncology portfolio, Eli Lilly and Company has entered into a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion. The transaction includes an upfront cash payment along with additional milestone-based payouts tied to clinical and regulatory progress.
The acquisition is centered around Ajax’s lead drug candidate, AJ1-11095, an investigational once-daily oral therapy currently in early stage (Phase 1) clinical trials. The drug targets the JAK2 protein, a key driver of certain blood cancers, including myelofibrosis a rare and chronic condition affecting bone marrow function.
Unlike existing treatments that bind to the “Type I” form of JAK2, AJ1-11095 is designed as a first in class Type II JAK2 inhibitor, potentially offering deeper and more durable responses for patients who become resistant to current therapies.
This acquisition aligns with Lilly’s broader strategy to strengthen its oncology pipeline, particularly in hematologic cancers. The company has been actively investing in next generation cancer therapies through a series of acquisitions, aiming to diversify its future revenue streams beyond its current blockbuster segments.
Industry analysts view the deal as part of a growing trend where large pharmaceutical companies are acquiring innovative biotech firms to access cutting edge science and accelerate drug development. By integrating Ajax’s research capabilities with its own global scale, Lilly aims to bring new treatment options to patients faster.
If successful, the acquisition could significantly enhance Lilly’s position in the competitive blood cancer treatment market, especially in areas with high unmet medical need.
“This deal reflects a bold push toward next-generation, more durable therapies for patients with hard to treat blood cancers.”
By
HB Team
Related News
